Table 2.
Treatment |
P value |
|||||||
---|---|---|---|---|---|---|---|---|
Time to storage (h) | Control | KP 300 mg | KP 450 mg | KP 600 mg | SEM | Treatment | Time to storage | Interaction |
MOT (%) | ||||||||
0 | 92.98a,v | 92.67a,v | 93.65a,v | 94.79a,v | 0.41 | <0.001 | <0.001 | <0.001 |
12 | 78.77d,w | 82.25c,w | 86.96b,w | 88.66a,w | 0.45 | |||
24 | 70.12c,x | 71.19c,x | 80.58b,x | 83.02a,x | 0.35 | |||
36 | 50.77c,y | 54.00b,y | 52.77b,y | 55.52a,y | 0.36 | |||
48 | 46.35c,z | 46.89c,z | 49.16b,z | 52.12a,z | 0.29 | |||
PMOT (%) | ||||||||
0 | 81.52c,v | 82.29bc,v | 83.31b,v | 86.91a,v | 0.46 | <0.001 | <0.001 | <0.001 |
12 | 70.74c,w | 70.28c,w | 74.04b,w | 81.04a,w | 0.90 | |||
24 | 64.10d,x | 66.30c,x | 69.83b,x | 76.35a,x | 0.98 | |||
36 | 37.70c,y | 39.92b,y | 43.45b,y | 45.24a,z | 0.49 | |||
48 | 36.67b,z | 37.43b,y | 37.32b,z | 41.44a,y | 0.65 | |||
Viability (%) | ||||||||
0 | 93.69c,v | 92.89bc,v | 94.15ab,v | 95.58a,v | 0.34 | <0.001 | <0.001 | <0.001 |
12 | 87.53c,w | 85.67c,w | 89.04b,w | 90.87a,w | 0.29 | |||
24 | 83.15c,x | 81.11c,x | 83.28b,x | 87.15a,x | 0.56 | |||
36 | 68.90d,y | 73.85c,y | 75.82b,y | 78.73a,y | 0.79 | |||
48 | 64.77c,z | 68.00b,z | 68.54b,z | 73.18a,z | 0.71 | |||
MDA (250 × 106 spz/nmol/mL) | ||||||||
0 | 1.33b,v | 1.20ab,v | 1.13a,v | 1.07a,v | 0.03 | <0.001 | <0.001 | <0.001 |
12 | 1.75b,w | 1.76b,w | 1.54ab,w | 1.46a,w | 0.04 | |||
24 | 2.32b,x | 2.38ab,x | 2.27ab,x | 2.23a,x | 0.05 | |||
36 | 2.46a,x | 2.48a,x | 2.45a,x | 2.44a,y | 0.05 | |||
48 | 2.80a,y | 2.79a,y | 2.75a,y | 2.68a,z | 0.03 |
Percentage of total motility (MOT); progressive motility (PMOT); malondialdehyde (MDA); values within a row with different superscript letters (a,b,c,d) indicate significant differences between treatments; values within a column with different superscript letters (v,w,x,y,z) indicate significant differences between storage times.
Boldface indicates p < 0.05.